Clinical Trial Landscape of PI3K Inhibitors in Breast Cancer: 87 Trials Analyzed

A dataset of 87 clinical trials on PI3K inhibitors for breast cancer treatment, compiled from eight major databases up to January 1, 2026. The analysis was conducted by Junjie Cao and includes descriptive statistics on trial phases, targets, agents, efficacy, and safety. The dataset was last updated on April 13, 2026.

Use Cases

• Analyze geographic distribution of clinical trial activity based on the description of leading regions and collaborative networks.
• Compare efficacy and safety profiles of different PI3K inhibitor agents and targets based on reported progression-free survival and adverse events.
• Study publication bias in clinical research based on the reported rate of over 60% of trials involving key targets remaining unpublished.

Strengths

• Data is sourced from eight major clinical trial databases, suggesting a systematic collection.
• Analysis includes 87 trials with inter-rater agreement assessed using Cohen’s kappa, indicating a review process.
• Specific findings are reported, such as Phase I trials accounting for 34.5% and PI3Kα being the target in 46 trials.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 28.5 KB DOCX file, indicating a limited scope likely focused on summary analysis rather than raw trial data.

Provenance

Source

figshare, authored by Junjie Cao.

Collection Method

Searched eight major clinical trial databases using standardized MeSH/Emtree terms; 87 trials were included for descriptive statistical analysis using R and SPSS.

Time Range

Trials searched up to January 1, 2026.

Freshness

Last updated 2026-04-13 04:35:16; freshness should be verified.

Geography

Global, with specific mention of the United States, Europe, China, and Korea.